Cargando…
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
BACKGROUND: In the Middle East, there is lack of data on peripheral blood CD34+stem cells mobilization by using biosimilar filgrastim. We have been using both Neupogen and a biosimilar G-CSF) Zarzio(®) (as a mobilizing agent since February 2014 for both allogenic and autologous stem cell transplanta...
Autores principales: | Islami, Maha M., Khan, Mansoor Ahmed, Aseeri, Mohammed A., Alshamrani, Majed A., Alnatsheh, Abdelmajid, Alamoudi, Sameer, Alzahrani, Ahmed A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990321/ https://www.ncbi.nlm.nih.gov/pubmed/36864713 http://dx.doi.org/10.12659/AOT.938585 |
Ejemplares similares
-
Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective
por: Khan, Mansoor A., et al.
Publicado: (2019) -
Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors
por: AlHarbi, Atika, et al.
Publicado: (2022) -
Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors
por: Farhan, Roiya, et al.
Publicado: (2017) -
Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization
por: Husian, Sadik, et al.
Publicado: (2021) -
PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM
por: Marchesi, Francesco, et al.
Publicado: (2023)